To determine the outcomes of women with isolated locoregional recurrence (LRR) of breast cancer treated with high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) following conventional therapy, we conducted a retrospective review of 58 patients from five institutions treated between 1990 and 1998. Forty-five patients (78%) had у2 poor prognostic factors ( 
breast cancer. The management of patients with LRR depends, in part, on whether primary treatment included mastectomy or breast conservation surgery and radiation therapy (RT).
The reported incidence of LRR following mastectomy has varied from 5 to 38%. [1] [2] [3] [4] [5] [6] [7] The early literature, which describes the outcomes of women with LRR following mastectomy, evaluated primarily local therapeutic options including either RT and/or surgical therapy. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The 5-year progression-free survival (PFS) and overall survival (OS) in these series ranged between 13-37% and 21-50%, respectively. However, since LRR following mastectomy is usually an initial manifestation of systemic disease, it is logical to combine systemic therapy with local treatment. One prospective randomized trial showed that in patients with estrogen receptor positive disease (ERϩ) tamoxifen following locoregional therapy significantly increased the 5-year disease-free survival (DFS). 21 The role of systemic chemotherapy in patients with LRR following mastectomy is less clear. There are no published data available from a prospective randomized clinical trial and data from retrospective series are conflicting. [22] [23] [24] [25] After breast conservation surgery and RT for early stage breast cancer, the incidence of LRR is approximately 10-20% at 10 years. 26, 27 The standard treatment for isolated breast recurrences in such patients is mastectomy, with a majority of patients alive at 5 years after surgery. In general, recurrence of cancer in the residual breast tissue after conservative surgery and RT has a better prognosis than local recurrence after mastectomy. [28] [29] [30] [31] However, early ipsilateral recurrence in the breast parenchyma and LRR involving the skin and nodes are significant predictors for subsequent distant metastases, uncontrolled local disease, and poor survival. 32, 33 No data are available which describe the outcomes of patients with isolated LRR consolidated with HDCT and ASCT following conventional therapy. We, therefore, performed a retrospective review and analysis of data from five institutions to address this issue.
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Materials and methods
Patients
Fifty-eight patients with LRR breast cancer (as defined earlier) who were enrolled on HDCT trials between June 1990 and November 1998 at Washington University (n = 36), University of Rochester (n = 9). Georgetown University (n = 7), Carolinas Medical Center (n = 3), and University of Texas Health Sciences Center (n = 3) comprised this retrospective analysis. All patients had no evidence of distant metastatic disease when diagnosed with LRR based on physical examination, chest X-ray, abdominal computed tomography, and bone scan. Computed tomography of the chest and brain and bone marrow biopsies were not required. All patients participated in clinical trials approved by the Institutional Review Board at each site, and gave written, informed consent. Minimal criteria for eligibility to proceed with HDCT included Karnofsky performance status у80%, age р70 years, left ventricular ejection fraction Ͼ45% as documented by cardiac radionuclide-gated pool scanning (MUGA) or echocardiogram, and adequate hepatic (serum bilirubin р2 mg/dl, and AST and ALT р3 times normal) and pulmonary function (diffusion capacity Ͼ40% of predicted).
Treatment
At the initial diagnosis of LRR, a complete resection of the macroscopic recurrence was attempted. Conventional-dose chemotherapy was given to most patients prior to HDCT and loco-regional radiation therapy was given either before or after HDCT. The choice of conventional-dose chemotherapy and timing of radiation was at the discretion of the physician, whereas the choice of HDCT regimen used depended on the HDCT protocol employed at each of the five transplant institutions. HDCT conditioning regimens included ( ). Tamoxifen was given to patients with ER positive breast cancer who had not received prior hormonal therapy. In patients who had been treated with tamoxifen prior to LRR, the choice of second-line hormonal agent was either megesterol acetate or anastrazole. The three patients treated at Georgetown University also received р4 weeks of interleukin-2 in the post-transplant period.
Study design
A retrospective review of the medical records of breast cancer patients with isolated LRR treated with HDCT and ASCT at these five institutions was conducted. Data collected included characteristics of the primary tumor (date and age of the patient at diagnosis, size of tumor, axillary lymph node status, hormone receptor status and therapy), the LRR (date and location of recurrence, extent of resection, chemotherapy, RT and response to pre-transplant therapy), HDCT treatment, post-transplant therapy and patient outcome (at last follow-up, survival post transplant and, where applicable, date and site of initial disease progression and date of death). Information was not available regarding size of the primary in eight patients, adjuvant radiation for the primary in four, disease status pre-transplant in three, number of involved lymph nodes at diagnosis of primary in one, and ER/PR status in one.
Definitions and statistical methods
Data were summarized as the mean or median Ϯ s.d. or range, for continuous variables as frequencies, and for categorical variables as percents. Outcomes examined included overall and progression-free survival, and were calculated from date of stem cell infusion. OS was defined as time to death from any cause. PFS was defined as time to progression of loco-regional disease or appearance of distance metastases. The technique of Kaplan-Meier (KM) was used to calculate actuarial probabilities. Univariate survival analyses were performed to examine factors potentially associated with PFS and OS from transplant. Factors examined included age (Ͻ50 vs у50 years), type of surgery for the primary tumor (conservative vs mastectomy), size of the primary tumor (р2 cm vs Ͼ2 cm), positive axillary lymph nodes (0 vs 1-9 vs у10), estrogen receptor status (positive vs negative), adjuvant chemotherapy (yes vs no), adjuvant radiation (yes vs no), site of the recurrence (chest wall vs nodal), presence of supraclavicular node involvement at recurrence (yes vs no), disease-free interval (DFI) from diagnosis of primary tumor to LRR (р2 years vs Ͼ2 years), number of recurrences (1 vs Ͼ1) complete excision of recurrence (yes vs no), timing of radiation for the recurrence (pre-vs post transplant), disease status at transplant (CR vs not in CR). The DFI was defined as the interval between diagnosis of the primary tumor and the initial recurrence. Multivariate analysis was performed using the factors identified to be potentially significant (P р 0.15) in the univariate analysis. Proportional hazards modeling of survival was performed using these candidate variables.
Results
Patient characteristics
Fifty-eight patients with LRR breast cancer were treated with surgery, conventional-dose chemotherapy, RT and HDCT. Table 1 outlines the characteristics of these patients at the time of their initial breast cancer. Of the 20 patients who received RT to the chest wall Ϯ regional lymphatics, 14 received it following a lumpectomy and six following a mastectomy. Three patients recurred soon after lumpectomy and before RT could be administered. The characteristics of patients at diagnosis of LRR are presented in Table  2 . Of the patients with chest wall recurrence only following lumpectomy, only one had an operable recurrence limited to the parenchyma of the breast. This patient had a DFI of Ͻ2 years.
Therapy for LRR
Details of therapy are shown in patients received a taxane, 23 received an anthracycline and five received both. Eleven patients received no conventional chemotherapy for their pre-transplant recurrence (seven of these patients were in CR following surgery and/or RT at the time of transplant, two had progressed locally just prior to planned HDCT for high-risk primary tumors, two patients were taken to HDCT without pretransplant chemotherapy). The disease status of three patients just prior to HDCT could not be ascertained from their records. All patients received autologous peripheral blood stem cells as the source of stem cells. There was no transplant-related mortality. A total of 53 patients received RT for LRR either pre-or post transplant. Five patients did not receive RT for their LRR: three patients recurred after HDCT and before planned RT, one patient had inadequate platelet recovery following HDCT and one patient refused RT.
Survival analysis
After a median follow-up of 14.2 (0.5-72) months, 36 patients (62%) developed progressive disease. Disease progression occurred at either local (27) or distant (nine) sites. Median time to disease progression following ASCT was 6.1 (1.3-31.4) months. At last follow-up, 23 patients (40%) had expired, all due to disease progression, and 35 patients (60%) were alive (13 with and 22 without progressive disease). The median follow-up of the 23 patients who were progression-free was 13.4 (0.5-72.3) months. By KM analysis, the estimated median PFS and OS for all patients was 20.3 and 29.2 months, respectively ( Figure 1 ). The KM estimates of 2 year PFS and OS rates were 47% and 58%, respectively.
Analysis of prognostic factors
Several variables were evaluated by univariate and multivariate KM survival analyses to identify factors potentially associated with OS and PFS. Of the variables examined by univariate analysis, the only factors associated with better OS and PFS from transplant were attainment of CR prior to transplant, complete excision of LRR, and LRR following a mastectomy (Table 4 ). Prior studies demonstrated that poor prognostic factors (PPF) in patients with LRR included DFI р2 years, hormone receptor negative or hormone refractory disease, and incomplete resection of the recurrence. In this study, the primary tumors were ER negative in 36 patients and 10 other patients had recurred while receiving tamoxifen. Thirty-six patients had an incomplete resection of the tumor recurrence, and the DFI was р2 years in 34 patients. The numbers of patients with one or less, two and three PPF were 13, 28, 17 patients, respectively. Patients with two or more PPF had a poorer PFS when compared to patients with none or one PPF; although OS was not significantly different. Other factors examined were not significantly associated with OS or PFS. Results of a multivariate analysis are shown in Table 5 . Improved PFS was predicted by ER positive disease and CR at HDCT. ER positive disease and CR at HDCT were also predictive of OS.
Discussion
Treatment approaches for isolated LRR following mastectomy included resection, RT, systemic therapy, or a combined modality approach. Only one randomized study has examined the role of hormonal therapy for isolated LRR following mastectomy. 21 In this study, the 5-year DFS rates were 59% and 36% with and without tamoxifen, respectively; however, the 5 year OS was approximately 75% in both arms of the study. These data may represent the best outcomes expected with current therapy for LRR, since eligible patients for this trial were required to have small volume recurrence which could be completely excised, estrogen receptor (ER) positive recurrence, or a disease-free interval (DFI) of у12 months if the receptor status was unknown. The role of systemic chemotherapy for women with isolated LRR of breast cancer following mastectomy has not been addressed in a prospective randomized trial. Several retrospective series attempted to address this ques- Bone Marrow Transplantation tion ( Table 6 ). The limitations of these retrospective studies and their conflicting outcomes preclude any firm conclusion regarding the role, if any, of conventional-dose chemotherapy after local therapy for isolated LRR following mastectomy. Analysis of prognostic factors has shown that results appeared to be optimal when, excision of the macroscopic recurrence was complete, and was followed by at least 4500 cGy of involved field RT. 9, 11, 12, 20 Other factors associated with a favorable prognosis included DFI Ͼ2 years and ER positive recurrence; whereas factors associated with a poor prognosis included recurrence in a supraclavicular node, combined chest wall and nodal recurrence, multiple recurrences or largest recurrence Ͼ1 cm. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In some series, characteristics of the primary tumor have had prognostic significance. 9, [13] [14] [15] [16] [17] 23, 24 These studies were all limited by their design (mostly retrospective or noncontrolled), small patient numbers, variable treatments administered, and/or short follow-up.
The standard treatment for relapses within the breast parenchyma after primary breast conservation surgery is a mastectomy. The role of adjuvant systemic therapy after mastectomy for recurrent disease after breast conservation therapy is unclear. However, Haffty et al 32 published that 50% of patients who developed an ipsilateral breast recurrence within 4 years of original diagnosis developed distant metastases. The 5 year post-breast recurrence survival rate for this group of patients was 0.50 Ϯ 0.10. Gage et al 33 published that the prognosis after local recurrence was poorer for patients with skin recurrence and invasive breast recurrence. They found that 44% of patients with skin recurrence had distant metastasis simultaneously or within 2 months of the recurrence as compared with 5% of invasive breast recurrences alone. Given that the 5 year actuarial survival rates were 34% and 77% for these two cohorts, respectively, it appears logical to add systemic therapy for this high risk group of patients as well.
To our knowledge, our report represents the first attempt to analyze the outcomes of women with isolated LRR of breast cancer treated with HDCT and ASCT in addition to conventional therapy. In this group of 58 patients, the median PFS and OS were 20.3 and 29.2 months, respectively; whereas, the 2 year PFS and OS were 47% and 58%, respectively. The results of this patient cohort were inferior to those reported by Buzdar et al 24 and Halverson et al 23 who used conventional therapy, including chemotherapy, for LRR. Although these data would suggest no obvious additive benefit of HDCT and ASCT in women with isolated LRR, this comparison may not be valid due to the inherent limitations of using historical control data and performing retrospective analyses. The inferior results observed in our patients may reflect an inherently poorer prognosis in our cohort. Indeed, all but three of the 58 patients in this study had at least one PPF when diagnosed with isolated LRR, and 78% had у2 PPF present. When compared with results observed with HDCT for patients with distant metastases, the results of our patients with LRR treated with HDCT appear similar. The ABMTR reviewed their data on patients with metastatic breast cancer and reported 3 year PFS and OS of 18% and 30%, respectively. 35 Bezwoda et al 36 reported median PFS and OS of 20 months and 22.5 months, respectively, for patients Table 6 Summary of retrospective studies comparing systemic chemotherapy following loco-regional therapy to loco-regional therapy alone F/U = follow-up; DFS = disease-free survival; OS = overall survival; LRT = loco-regional therapy; CT = chemotherapy; NS = not significant.
treated on the high-dose arm of their randomized trial.
Stadtmauer et al 37 reported a 3 year OS of 32% for patients with metastatic disease treated with HDCT. Most patients in these series had visceral or bone disease. Carter et al 38 recently reviewed their data on patients with locally and/or regionally recurrent breast cancer treated with HDCT, looking at the outcome of patients who received consolidative radiation for loco-regional disease compared to patients who received HDCT alone. Although a majority of patients in this series had LRR, patients with bony and visceral metastases were included as well. The 4 year actuarial EFS and OS for the entire group of patients who received HDCT followed by RT were 31% and 30%, respectively. However, no subset analysis for the group with LRR was presented and no prognostic factors were analyzed. There are four large series in the literature, looking at factors correlated with survival after HDCT for metastatic breast cancer. [39] [40] [41] [42] Dunphy et al 42 in their series of 80 patients identified soft tissue relapse as a factor predictive of a poor outcome. Patients with a soft tissue relapse and lymph node metastases had a 2 year estimated PFS of 4.6% and 8.7%, respectively, and an OS of 14.9% and 25%, respectively. In the other series, soft tissue relapse did not predict for survival.
In this study, an analysis of prognostic factors revealed that response to pre-transplant conventional therapy was highly predictive of PFS and OS. On univariate analysis, patients relapsing following a mastectomy had significantly better PFS and OS than patients relapsing following a lumpectomy. This is probably due to the presence of poor prognostic factors including bulky unresectable tumors and/or skin involvement in nearly all the patients transplanted for a post-lumpectomy LRR. Patients who had recurrences completely excised had better PFS and a trend towards better OS on univariate analysis. Complete excision for LRR following mastectomy has been a favorable prognostic factor in several series of patients treated with conventional therapy. 9, 11, 12, 20 Patients with ER positive tumors demonstrated a trend to better OS on univariate analysis, and in the multivariate model, predicted for both improved PFS and OS. This is in concordance with the overall favorable outlook of patients with ER positive disease. However, in contrast to several series of conventional therapy for LRR and of HDCT for metastatic disease, DFI was not predictive of PFS or OS in our study. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The site of recurrence and involvement of supraclavicular nodes did not predict for PFS or OS.
In conclusion, the overall survival of this cohort of patients with LRR treated with HDCT in addition to conventional therapy was similar to those treated with conventional therapy alone, and to those with distant metastases treated with HDCT. These patients did not appear to constitute a favorable subgroup of metastatic breast cancer patients, perhaps as a result of most patients having had several PPF. Whether the results of HDCT would be better for patients with LRR displaying more favorable characteristics is unclear. However, given that 75% of our patients who progressed following HDCT developed local progression of their disease, better measures for local disease control should be a focus for further research in these patients.
